Incyte | Actif À Court Terme



Current Assets Changement Date
Acadia Pharmaceuticals USD 938.32M 150.03M 2024-12
Agios Pharmaceuticals USD 965.6M 108.59M 2024-12
Alnylam Pharmaceuticals USD 3.3B 60.14M 2024-12
Amgen USD 29.03B 2.26B 2024-12
Biogen USD 7.46B 626.3M 2024-12
BioMarin Pharmaceutical USD 3.23B 175.84M 2024-12
Bristol-Myers Squibb USD 30.78B 1B 2025-03
Eli Lilly USD 41.26B 8.52B 2025-03
Exelixis USD 1.47B 82.14M 2025-01
Gilead Sciences USD 19.17B 4.39B 2024-12
Incyte USD 3.23B 7.24M 2025-03
Ionis Pharmaceuticals USD 2.42B 201.36M 2025-03
MacroGenics USD 217.49M 4.71M 2024-12
Merck USD 38.78B 1.58B 2024-12
Moderna USD 6.77B 1.33B 2025-03
Neurocrine Biosciences USD 1.72B 151.9M 2024-12
Novartis USD 29.7B 1.56B 2024-12
Novartis USD 29.7B 1.56B 2024-12
Pfizer USD 50.36B 7.14B 2024-12
PTC Therapeutics USD 1.37B 83.98M 2024-12
Regeneron Pharmaceuticals USD 17.57B 9.64B 2025-03
Sarepta Therapeutics USD 3.07B 388.09M 2024-12
Ultragenyx Pharmaceutical USD 817.12M 17.52M 2024-12
Vertex Pharmaceuticals USD 9.6B 207.7M 2024-12



Incyte Actif À Court Terme - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - May 2025.